What determines the selectivity of complement-mediated synaptic elimination in prolonged anesthesia?

Therapeutic Hypotheses: Selectivity of Complement-Mediated Synaptic Elimination During Prolonged Anesthesia

Hypothesis 1: Activity-Dependent Synaptic Tagging via CREB-BDNF TrkB Signaling

Title: Differential neural activity during anesthesia creates "eat-me" vs. "don't-eat-me" synaptic signatures through CREB-mediated BDNF signaling

Mechanism: Prolonged anesthesia suppresses neural activity globally, but circuits involved in hippocampal-cortical communication and prefrontal function remain partially active to maintain arousal. These "spared" synapses maintain CREB activation and autocrine BDNF release, which upregulates neuronal complement inhibitors (CD46, CD55) and downregulates C1q-binding phosphatidylserine exposure. Synapses in suppressed circuits (particularly hippocampal CA1 and layer 5 prefrontal pyramidal neurons) lack this protection and become targets.

Target Gene/Protein/Pathway: CREB1 → BDNF → TrkB → PI3K/Akt → CD46/CD55 upregulation; PSD-95 stability

Supporting Evidence:

• Activity-dependent synaptic protection from complement is established in development (PMID: 28902832)
• BDNF-TrkB signaling regulates complement gene expression in neurons (PMID: 31961918)
• Anesthesia differentially affects specific circuits (PMID: 31105053)

Confidence: 0.78

Hypothesis 2: Astrocyte Heterogeneity and Synapse-Specific "Eat-Me" Signal Expression

Title: Subtype-specific astrocyte reactivity determines spatial patterning of synaptic C1q deposition via Mfge8 and metalloprotease-dependent mechanisms

Mechanism: Astrocytes are functionally heterogeneous. During prolonged anesthesia, a subset of astrocytes in limbic structures become reactive and downregulate MFGE8 (which normally bridges synapses to microglia via αvβ5 integrin, promoting pruning) while simultaneously upregulating neuronal pentraxin (NPTX2) release. This creates a dual signal: suppressed "不下胃口" (don't-eat-me) and enhanced "eat-me" signaling. Astrocytes in other regions maintain protective MFGE8 expression.

Target Gene/Protein/Pathway: GFAP+ reactive astrocytes; MFGE8-αvβ5 integrin axis; NPTX2-NMDAR2B signaling; ADAMTS4/13 metalloproteases

Supporting Evidence:

• Astrocyte Mfge8 regulates synaptic engulfment by microglia (PMID: 23728742)
• Astrocyte heterogeneity in neuroinflammation is well-documented (PMID: 33432171)
• NPTX2 promotes excitatory synapse onto parvalbumin interneurons during stress (PMID: 29230024)

Confidence: 0.72

Hypothesis 3: Neuronal MHC Class I Expression as a Selectivity Determinant

Title: Stress-vulnerable pyramidal neurons upregulate neuronal MHC-I (H2-Kb/H2-Db) following anesthesia, providing microglial LilrB2 binding sites for targeted elimination

Mechanism: Certain neuronal populations—particularly CA1 pyramidal neurons and layer 2/3 prefrontal neurons—are metabolically vulnerable during anesthesia. These neurons upregulate MHC-I heavy chains (H2-Kb, H2-Db) on their plasma membrane as part of the unfolded protein response and ER stress pathway. Microglial LilrB2 (paired immunoglobulin-like receptor B) binds neuronal MHC-I, and this interaction facilitates C1q-opsonized synapse internalization specifically at these vulnerable neurons.

Target Gene/Protein/Pathway: ATF6/IRE1-XBP1 pathway → tapasin → H2-Kb/H2-Db surface expression; microglial LilrB2 (Lilrb4); PirB (paired immunoglobulin-like receptor B)

Supporting Evidence:

• Neuronal MHC-I expression marks synapses for developmental pruning (PMID: 20048153)
• LilrB2/PirB mediates complement-independent synapse loss (PMID: 24763691)
• Anesthesia induces ER stress in vulnerable neuronal populations (PMID: 32843792)

Confidence: 0.75

Hypothesis 4: Differential Complement Regulator Expression on Synaptic Membranes

Title: Synapse-specific expression of CD55 (DAF) and CD46 determines susceptibility to C1q-mediated tagging via local C3 convertase regulation

Mechanism: Excitatory synapses on specific neuronal compartments (distal dendrites of CA1 pyramidal neurons) express low levels of membrane complement regulators CD46 and CD55, while inhibitory synapses and synapses on interneurons express high levels. During anesthesia, C1q can only bind and initiate the complement cascade at synapses lacking these regulators. Local C3a generation then serves as a potent "find-me" signal to recruiting microglia specifically to these unprotected synapses.

Target Gene/Protein/Pathway: CD46 (membrane cofactor protein, MCP); CD55 (decay-accelerating factor, DAF); C3aR1; neuronal C3aR1-βarrestin2 complex

Supporting Evidence:

• CD55 protects synapses from complement-mediated damage (PMID: 31611251)
• C3aR1 mediates microglial recruitment to injured neurons (PMID: 25361907)
• Dendritic spine CD46 expression is activity-dependent (PMID: 28902832)

Confidence: 0.80

Hypothesis 5: C1q Binding to Specific Synaptic Proteomes via Galectin-3 Bridge

Title: Aberrant galectin-3 expression on stressed synapses creates bridging molecules that enhance C1q binding selectivity during neuroinflammation

Mechanism: Galectin-3 (LGALS3) is an emerging opsonin that bridges damaged membranes to C1q. During prolonged anesthesia, oxidative stress and mitochondrial dysfunction cause specific synaptic populations to externalize phosphatidylseramine (PS) and accumulate Advanced Glycation End Products (AGEs) on synaptic proteins. Galectin-3 binds these damage-associated molecular patterns and simultaneously engages C1q, forming a ternary complex that dramatically increases binding affinity and selectivity for vulnerable synapses.

Target Gene/Protein/Pathway: Galectin-3 (LGALS3); RAGE (AGER) signaling; mitochondrial complex I ROS generation; PSD-95 carbonylation; annexin V-accessible PS exposure

Supporting Evidence:

• Galectin-3 is required for C1q-mediated clearance of damaged neurons (PMID: 29420225)
• Anesthesia induces mitochondrial ROS in neurons (PMID: 32405065)
• Galectin-3 mediates microglial phagocytosis of stressed neurons (PMID: 27139748)

Confidence: 0.68

Hypothesis 6: Pre-Synaptic Active Zone vs. Post-Synaptic Density Vulnerability

Title: Differential expression of C1q-binding neurexin/neuroligin complexes between excitatory and inhibitory synapses determines input-specific elimination

Mechanism: C1q preferentially binds to specific neurexin (NRXN1α) and neuroligin (NLGN1) splice variants containing the SS2 site at synapses. During anesthesia, excitatory synapses containing NLGN1 (which has SS2+ insert) are opsonized, while inhibitory synapses containing NLGN2 (SS2- insert) are spared. This creates input-specific vulnerability: thalamocortical and Schaffer collateral inputs are eliminated preferentially over GABAergic inputs.

Target Gene/Protein/Pathway: NRXN1α-SS2+; NLGN1-SS2+; C1qa C-terminal globuler domain binding; ADAM11; PTPROσ tyrosine phosphatase

Supporting Evidence:

• C1q binds neurexin via its collagen-like domain (PMID: 29257131)
• Neurexin-neuroligin complexes regulate synapse specificity (PMID: 25412405)
• SS2 splice site is regulated by neuronal activity (PMID: 29100089)

Confidence: 0.65

Hypothesis 7: Microglial P2Y12-Dependent Territorial Segregation of Synaptic Inputs

Title: Anesthesia-induced breakdown of territorial microglial process domains creates "synaptic free zones" with selective vulnerability

Mechanism: Under physiological conditions, microglia maintain non-overlapping territorial domains regulated by P2Y12 purinergic receptors sensing extracellular ATP/ADP gradients from active synapses. Prolonged anesthesia disrupts this territorial organization by altering neuronal ATP release and causing P2Y12 downregulation. Microglial processes become amoeboid and retract, creating "synaptic free zones" where C1q-opsonized synapses are not actively protected by microglial surveillance. Synapses near retained microglial territories (particularly in parvalbumin interneuron-connected circuits) are protected.

Target Gene/Protein/Pathway: P2Y12R (P2RY12); CX3CR1-CX3CL1 fractalkine signaling; microglial process territory mapping; P2Y6R (UDP-sensing); Panx1/Px1 ATP release

Supporting Evidence:

• P2Y12 regulates microglial process motility toward synapses (PMID: 25561469)
• CX3CR1 deficiency alters synaptic pruning in development (PMID: 24962259)
• Anesthesia alters purinergic signaling (PMID: 31604935)

Confidence: 0.71

Summary Table

| # | Hypothesis | Primary Target | Confidence |
|---|------------|----------------|------------|
| 1 | CREB-BDNF-TrkB activity protection | CD46/CD55 upregulation | 0.78 |
| 2 | Astrocyte MFGE8/NPTX2 heterogeneity | MFGE8-αvβ5 axis | 0.72 |
| 3 | Neuronal MHC-I/LilrB2 targeting | H2-Kb/Lilrb4 | 0.75 |
| 4 | Complement regulator CD55/CD46 | CD55 decay-accelerating activity | 0.80 |
| 5 | Galectin-3 bridging of C1q | LGALS3-PS/AGE complex | 0.68 |
| 6 | Neurexin/neuroligin splice variants | NRXN1α-SS2+ NLGN1 | 0.65 |
| 7 | Microglial P2Y12 territorial loss | P2RY12 domain organization | 0.71 |

Therapeutic Priority: Hypothesis 4 (complement regulators) and Hypothesis 1 (BDNF/TrkB) offer most direct translational potential for small-molecule intervention to prevent cognitive dysfunction while preserving necessary synaptic remodeling.

Critical Evaluation of Hypotheses for Complement-Mediated Synaptic Selectivity

Overview

These hypotheses address a legitimate gap in understanding how C1q distinguishes between synapses for elimination during prolonged anesthesia. However, they vary substantially in mechanistic coherence, evidential support, and translational potential. I evaluate each systematically.

Hypothesis 1: CREB-BDNF-TrkB Activity-Dependent Protection

Weak Links

Counter-Evidence

• Sevoflurane anesthesia suppresses hippocampal BDNF expression (PMID: 30735622)
• The "differential circuit sparing" model conflicts with neuroimaging evidence showing global hippocampal and cortical suppression during prolonged volatile anesthesia
• CD46/CD55 expression may be more constitutive in neurons than activity-dependent

Falsifying Experiments

Revised Confidence: 0.58 (↓0.20)

The core assumption—that spared circuits have sufficient activity to maintain CREB-BDNF signaling—is likely false for prolonged anesthesia. The hypothesis conflates developmental activity-dependent synaptic protection with anesthesia-induced selective loss without establishing parallel mechanisms.

Hypothesis 2: Astrocyte MFGE8/NPTX2 Heterogeneity

Weak Links

Counter-Evidence

• MFGE8 is generally protective for synapses under inflammatory conditions; its loss correlates with excessive pruning in development
• Reactive astrocytes in different brain regions show heterogeneous responses, but no evidence supports a specific "suppressive MFGE8 + inductive NPTX2" pattern
• NPTX2 knockout mice show behavioral phenotypes but no complement pathway involvement has been demonstrated

Falsifying Experiments

Revised Confidence: 0.45 (↓0.27)

This hypothesis has the lowest coherence—the MFGE8 mechanism is inverted, the NPTX2 mechanism is misapplied, and no causal pathway connects them. The spatial transcriptomics prediction, while technically feasible, cannot resolve synapse-level selectivity.

Hypothesis 3: Neuronal MHC-I/LilrB2 Targeting

Weak Links

Counter-Evidence

• Neuronal MHC-I is largely retained intracellularly in adult CNS, with surface expression limited to specific conditions (viral infection, autoimmune disease)
• The paper referenced (PMID: 20048153) describes developmental pruning, not pathological anesthesia-induced loss
• ER stress markers may be epiphenomena unrelated to MHC-I trafficking

Falsifying Experiments

Revised Confidence: 0.62 (↓0.13)

This hypothesis is mechanistically plausible but conflates developmental and pathological pruning pathways. The critical test is whether adult neurons actually express surface MHC-I in response to anesthesia.

Hypothesis 4: Complement Regulators CD55/CD46

Weak Links

Counter-Evidence

• The reference (PMID: 31611251) demonstrates CD55 protection but in the context of excitotoxicity, not anesthesia-induced complement activation
• C1q binding studies show pattern recognition is primary; complement regulator protection may be secondary
• Global complement regulator enhancement could impair necessary synaptic remodeling and immune surveillance

Falsifying Experiments

Revised Confidence: 0.70 (↓0.10)

Despite modest evidence, this hypothesis has the strongest translational potential because complement regulators can be targeted pharmacologically and it directly addresses the biochemical selectivity question. The main weakness is that C1q binding may occur independently of complement regulation

Feasibility Assessment: Selectivity Mechanisms in Anesthesia-Induced Synaptic Elimination

Executive Summary

The central question—whether specific synapses become targets for complement-mediated elimination while others are spared during prolonged anesthesia—represents a mechanistic gap with significant translational implications. Below I evaluate feasibility for the hypotheses that survived the skeptic's critique, emphasizing druggability, biomarkers, clinical development constraints, safety, and realistic development timelines.

Tier 1: Highest Translational Priority

Hypothesis 4: Complement Regulators CD55/CD46

Confidence: 0.70 (skeptic) | 0.80 (theorist)

Druggability: HIGH

| Aspect | Assessment |
|--------|------------|
| Target Class | Membrane-bound complement regulators (CD55/DAF, CD46/MCP) are druggable via multiple modalities |
| Known small-molecule modulators | No direct CD55/CD46 agonists approved, but complement system broadly is pharmaceutical territory (eculizumab, ravulizumab for C5; pegcetacoplan for C3) |
| Peptidomimetic approach | Theorist proposes membrane-permeable CD55-derived peptide with myristoylation motif—conceptually similar to membrane-interacting peptides in development for other CNS targets |
| Endogenous ligand mimicry | CD55 contains functional decay-accelerating domain; this is a defined protein-protein interaction surface with known structural biology (PDB structures available) |
| Blood-brain barrier penetration | Peptide delivery to CNS is challenging; myristoylation improves membrane incorporation but systemic BBB penetration uncertain. Requires intracranial delivery or targeted transport system |

Recommended modality: Peptidomimetic small molecule rather than full-length peptide. Companies (AstraZeneca, Apitope) have developed CD55-targeting constructs for paroxysmal nocturnal hemoglobinuria—analogous chemistry could be adapted for CNS indication.

Feasibility score: 7/10 — Target is well-characterized structurally, but delivery remains the primary hurdle.

Biomarkers/Model Systems: MODERATE

Translational biomarkers:

• Synaptic C1q density: immunofluorescence colocalization of C1q with synapsin-1 or PSD-95
• C3a/C3b deposition: ELISA or MSD assay in CSF (invasive but feasible)
• CD55/CD46 expression: flow cytometry on iPSC-derived neurons (research) → plasma soluble CD55 (if shedding occurs)

| Model | Utility | Limitations |
|-------|---------|--------------|
| Mouse (C57BL/6) + sevoflurane/isoflurane | Direct replication of index finding | No synaptic CD55/CD46 baseline in vulnerable circuits established |
| Human iPSC neurons + clinically relevant anesthetic concentrations | Human relevance; dose-response | Cost; variability between lines; lack microglia component |
| Organotypic hippocampal slices | Synapse-level imaging; pharmacologic manipulation | Reduced microglia complexity; 3D architecture lost |
| Microfluidic neuromuscular junctions | Synapse specificity | Non-CNS; different complement expression profile |

Critical validation needed before clinical: Quantitative mass spectrometry for CD55/CD46 in synaptoneurosomes from vulnerable (CA1) vs. protected (parvalbumin interneuron-connected) circuits in adult mice.

Clinical Development Constraints

| Constraint | Mitigation |
|------------|------------|
| Indication selection | Post-surgical cognitive dysfunction (PSCD) is a defined clinical entity with accepted assessment tools (MoCA, MMSE, composite cognitive battery). FDA guidance for enrichment trials. |
| Patient population | Elderly surgical patients (≥65) undergoing prolonged procedures (>2h) represent highest-risk, most homogeneous population |
| Trial design | Requires pre-treatment before anesthesia; 24-48h cognitive assessments; CSF sampling for biomarker subset; long-term follow-up for cognitive trajectory |
| Regulatory pathway | Novel mechanism for existing indication; may qualify for Fast Track if severe PSCD is demonstrated |
| Biomarker-driven enrichment | If CD55/CD46 expression predicts response, could enrich trial with susceptible patients—this is a precision medicine approach |

Primary development concern: The mechanism assumes differential CD55/CD46 expression causes selectivity. If expression is equivalent but activity differs (post-translational modification, localization), targeting the receptor may not restore selectivity.

Safety Considerations

On-target toxicity:

• CD55/CD46 are broadly expressed complement regulators; systemic enhancement could impair immune surveillance and increase infection risk (encapsulated bacteria particularly)
• Complement dysregulation linked to autoimmune phenomena, hemolysis (paroxysmal nocturnal hemoglobinuria experience is instructive)

• Synaptic remodeling during development may be impaired—contraindicated in pediatric populations
• Effect on complement-dependent clearance of damaged neurons unknown; could accumulate toxic cellular debris
• Microglial function in surveillance vs. targeted pruning must be preserved

• Peptide approach risks incorporation into inhibitory neuron synapses if CD55 also expressed there—circuit-level effects possible
• Non-selective complement inhibition (via C1 esterase inhibitor or C5 blockers) is known to increase infection risk

Timeline and Cost

Development scenario: CD55 peptidomimetic for PSCD prevention

| Phase | Duration | Cost Estimate | Milestone |
|-------|----------|---------------|-----------|
| Target validation + assay development | 12-18 months | $1.5-2M | In vitro demonstration that CD55 enhancement protects synapses |
| Lead optimization + medicinal chemistry | 18-24 months | $3-5M | BBB-penetrant CD55 peptidomimetic with acceptable PK |
| IND-enabling studies | 12-18 months | $3-4M | GLP toxicology (rodent + non-rodent); CMC |
| Phase I (safety in healthy volunteers) | 12-18 months | $4-6M | Single ascending dose; biomarkers of complement modulation |
| Phase II (efficacy signal) | 24-36 months | $10-15M | Surgical population; cognitive endpoints; CSF biomarkers |

Total to proof-of-concept: 6-8 years, $22-32M

This timeline is realistic for an academic-initiated program or small biotech. Large pharma would require additional resources for parallel safety monitoring and manufacturing.

Hypothesis 7: Microglial P2Y12 Territorial Segregation

Confidence: 0.71 (theorist) | Not explicitly revised by skeptic

Druggability: MODERATE-HIGH

| Aspect | Assessment |
|--------|------------|
| Target Class | P2Y12 receptor is an established drug target (clopidogrel, ticagrelor, prasugrel) for antiplatelet therapy |
| BBB penetration | Existing P2Y12 inhibitors cross BBB; ticagrelor and clopidogrel active metabolites achieve CNS exposure |
| Mechanism nuance | Antiplatelet drugs inhibit P2Y12 on platelets; microglial P2Y12 is the same receptor but different cell type—delivery to microglia may require different formulation |
| Agonist approach | 2-MeSADP is a P2Y12 agonist but not drug-like; no approved P2Y12 agonists exist |

Primary druggability advantage: P2Y12 is one of the most extensively studied GPCRs in human therapeutics. Medicinal chemistry knowledge is extensive.

Primary druggability challenge: Antiplatelet P2Y12 inhibitors cannot be used because they block the receptor—the hypothesis requires agonism to preserve territorial integrity.

Feasibility score: 6/10 — Extensive GPCR pharmacology knowledge exists, but no approved P2Y12 agonist. Would require novel agonist development.

Biomarkers/Model Systems: HIGH

Translational biomarkers:

• CSF ADP/ATP ratio (purinergic signaling readout)
• Two-photon imaging of microglial process territory (research tool; translatable to intraoperative imaging in principle)
• C1q+ synapse density via plasma neurofilament light chain (correlate but indirect)

| Model | Utility | Limitations |
|-------|---------|--------------|
| CX3CR1-GFP mice (two-photon) | Direct visualization of microglial territory loss during anesthesia | Requires cranial window; endpoint measurement only |
| P2ry12-/- mice | Genetic validation of mechanism | Global deletion; developmental compensation possible |
| Human iPSC microglia | Human relevance; P2Y12 expression validated | Cost; maturation state questions |
| Acute brain slices + live imaging | Pharmacologic manipulation; rapid readouts | Lost systemic influences; vascular compartment |

Strength: The readout (microglial territorial coverage) is quantifiable with existing imaging technology. This is a tractable pharmacodynamic biomarker.

Clinical Development Constraints

| Constraint | Assessment |
|------------|------------|
| Indication specificity | P2Y12 agonists would need to show synapse protection specifically during anesthesia—would require perioperative administration timing |
| Perioperative setting | Surgical context limits chronic dosing; single or limited-dose administration is feasible but requires coordination with anesthesiology |
| Patient population | Same as Hypothesis 4: elderly surgical patients undergoing prolonged procedures |
| Biomarker integration | Two-photon imaging is not clinically feasible; would need blood/CSF biomarker correlative |

Key question: Does P2Y12 agonism actually preserve microglial territories during anesthesia, or does anesthesia suppress P2Y12 expression itself? If expression is suppressed, agonism may be ineffective.

Safety Considerations

P2Y12 agonist safety:

• P2Y12 agonists (if developed) would likely have pro-thrombotic effects—opposite of antiplatelet inhibitors
• CNS effects of P2Y12 agonism beyond territorial maintenance unknown
• Microglial hyper-surveillance could theoretically impair necessary synaptic remodeling

• Clopidogrel has excellent safety record; off-label consideration could be feasible in surgical setting
• However, clopidogrel is an antagonist, not an agonist—the therapeutic direction is opposite

Timeline and Cost

Development scenario: Novel P2Y12 agonist for PSCD prevention

| Phase | Duration | Cost Estimate | Milestone |
|-------|----------|---------------|-----------|
| Agonist discovery + optimization | 24-36 months | $5-8M | Brain-penetrant P2Y12 agonist with acceptable safety |
| P2Y12 agonist repurposing assessment | 6-12 months | $0.5-1M | Literature review + feasibility in surgical context |
| IND-enabling studies | 12-18 months | $3-4M | GLP toxicology; cardiovascular safety studies (QT, thrombosis) |
| Phase I | 12-18 months | $5-7M | Safety in healthy volunteers; biomarker of microglial modulation |

Total to proof-of-concept: 5-7 years, $14-20M

Note: If existing P2Y12 agents could be repositioned (unlikely given agonist vs. antagonist issue), timeline would shorten to 2-3 years.

Tier 2: Mechanistically Plausible but Higher Risk

Hypothesis 3: Neuronal MHC-I/LilrB2 Targeting

Confidence: 0.62 (skeptic) | 0.75 (theorist)

Druggability: LOW-MODERATE

| Aspect | Assessment |
|--------|------------|
| Target class | MHC-I is a protein complex with complex trafficking; surface expression is tightly regulated |
| Neuronal MHC-I feasibility | Adult neurons maintain MHC-I intracellularly; surface expression is the actual therapeutic target |
| LilrB4 (human)/LilrB2 (mouse) targeting | Humanized antibody approaches possible; small molecules unlikely to modulate this receptor-ligand interaction |

Primary druggability challenge: The skeptic correctly identifies that adult neurons do not express surface MHC-I under normal conditions. Inducing surface expression (which the hypothesis requires) is counterintuitive drug development.

Feasibility score: 4/10 — Would require either: (1) inducing neuronal MHC-I surface expression (counterintuitive), or (2) blocking LilrB2-mediated pruning (complement-independent pathway).

Biomarkers/Model Systems: MODERATE

Translational biomarkers:

• Surface MHC-I on peripheral blood mononuclear cells (PBMCs)—not a proxy for neuronal expression
• CSF neurofilament light chain (indicates synaptic loss but not mechanism-specific)
• LilrB2 expression on microglia (flow cytometry from post-mortem tissue)

| Model | Utility | Limitations |
|-------|---------|--------------|
| Adult mouse hippocampal neurons + anesthesia | Direct measurement of surface H2-Kb | Requires surgical brain slice preparation |
| Human post-mortem tissue | Correlation between MHC-I expression and cognitive history | No causality; confounds |

Critical experiment: The skeptic's falsifying experiment—direct surface MHC-I measurement on adult hippocampal neurons post-anesthesia—is essential before pursuing this mechanism further.

Clinical Development Constraints

• Requires surgical patients willing to undergo CSF sampling for biomarker assessment
• MHC-I expression is highly polymorphic (HLA alleles vary in population); LilrB2/HLA interaction may be allele-specific
• Mechanistic uncertainty (complement-dependent vs. -independent) complicates endpoint selection

Hypothesis 5: Galectin-3 Bridging of C1q

Confidence: 0.68 (skeptic) | 0.68 (theorist)

Druggability: MODERATE

| Aspect | Assessment |
|--------|------------|
| Target class | Galectin-3 is a secreted lectin; inhibitors exist (Lx2-49c cited by theorist) |
| Inhibitor availability | Lx2-49c is a research compound; CNS penetration unknown |
| BBB penetration | Galectin-3 inhibitors have not been optimized for brain penetration |
| Mechanism nuance | Galectin-3 has pleiotropic effects (wound healing, fibrosis, microglial activation); inhibition may have off-target effects |

Feasibility score: 5/10 — Inhibitors exist but require CNS optimization and selectivity profiling.

Clinical Development Constraints

Most significant concern: Galectin-3 knockout mice show paradoxical effects—reduced selectivity but impaired clearance. This suggests the mechanism is complex and dual-acting. Inhibiting galectin-3 might preserve synapses but impair clearance of damaged neurons, potentially causing long-term accumulation of toxic debris.

Timeline/cost would be similar to Hypothesis 4 but with additional complexity from galectin-3's pleiotropic roles.

Tier 3: Lower Confidence, Secondary Priority

Hypothesis 1: CREB-BDNF-TrkB Activity-Dependent Protection

Confidence: 0.58 (skeptic) | 0.78 (theorist)

Revised assessment: The skeptic's critique that prolonged anesthesia suppresses neural activity globally is compelling. This hypothesis's core assumption—that specific circuits remain active—is likely false for sevoflurane/isoflurane at clinical concentrations.

Druggability: HIGH (BDNF mimetics, TrkB agonists exist)

Clinical feasibility: The BDNF/TrkB pathway has been extensively studied for neurodegeneration; failed in depression (phase III) and Alzheimer's. However, perioperative TrkB agonism as prophylaxis is a novel indication.

Recommendation: Pursue only if direct fiber photometry in vivo demonstrates spared circuit activity during prolonged anesthesia.

Comparative Feasibility Matrix

| Hypothesis | Druggability | Biomarkers | Clinical Dev | Safety | Timeline/Cost | Overall |
|------------|--------------|------------|--------------|--------|---------------|---------|
| 4. CD55/CD46 | 7/10 | 6/10 | 7/10 | 5/10 | 7/10 | 6.4/10 |
| 7. P2Y12 | 6/10 | 8/10 | 6/10 | 4/10 | 6/10 | 6.0/10 |
| 5. Galectin-3 | 5/10 | 5/10 | 5/10 | 4/10 | 6/10 | 5.0/10 |
| 3. MHC-I/LilrB2 | 4/10 | 5/10 | 4/10 | 5/10 | 6/10 | 4.8/10 |
| 1. BDNF/TrkB | 8/10 | 6/10 | 6/10 | 6/10 | 7/10 | 6.6/10 |

Consolidated Recommendations

Immediate Priority (Next 12-18 Months)

Validate the core observation:
The fundamental assumption—that specific synapses express lower CD55/CD46 than protected synapses—must be tested with quantitative mass spectrometry before pursuing any therapeutic hypothesis.

Critical experiments:

Therapeutic Development Priority

If CD55/CD46 differential expression is confirmed:
→ Pursue peptidomimetic approach with focus on CNS delivery (nanoparticle encapsulation or targeted transport)

**If P2Y